Pain Therapeutic Injectables Market Snapshot (2023 to 2033)

The global pain therapeutic injectables market holds a valuation of US$ 19.3 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.

Market Outlook:

Data Points Market Insights
Market Value 2022 US$ 19.3 Billion
Market Value 2033 US$ 30.9 Billion
CAGR 2023 to 2033 4.5%
Market Share of Top 5 Countries 59.1%
Key Market Players AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P.

Therapeutic injections for treating pain can aid in reducing swelling and discomfort. Depending on the location, muscle injury, skeletal or neurological structures, and overall symptoms, there are choices for injectable treatment for almost any sort of pain a patient is experiencing. These injections can be administered intravenously, subcutaneously, or through an epidural catheter. These injectables are frequently used to treat acute pain which occurs because of injuries, post-operative pain, or chronic pain due to any kind of illness.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Pain Therapeutic Injectables Market from 2018 to 2022 Vs Market Outlook for 2023 to 2033.

The global market holds around 28.5% share of the overall global painkillers market with a value of around US$ 67.7 Billion, in 2022.

The increasing prevalence of chronic pain conditions, such as arthritis, cancer pain, and lower back pain, is one of the primary drivers of the pain therapeutic injectables market. These conditions require long-term pain management, which often includes the use of injectable pain medications. Due to the rise in chronic diseases, the market for pain therapeutic injectables has exhibited a consistent increase.

Apart from this, the market is anticipated to expand in the coming years because of the rising number of surgeries performed worldwide. This eventually demands post-operative pain management. Moreover, technological developments have led to improvements in drug delivery systems which ensures more accurate and effective administration of injectable drugs.

As the importance of pain management becomes more widely recognized, patients are seeking out effective pain relief options that can improve their quality of life. Pain therapeutic injectables are one such option that can provide rapid and effective relief from pain.

Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 30.9 billion in the year 2033.

What are the Key Opportunities for the Manufacturers Operating in the Global Market?

There are numerous potentials for innovation and expansion in the market for companies dealing in pain therapeutic injectables. The market is being driven by the rising demand for minimally invasive procedures worldwide. Minimally invasive procedures, such as injections, are becoming increasingly popular among patients due to their ability to reduce pain and discomfort while minimizing the risk of complications. This is driving the demand for pain therapeutic injectables, which can provide effective pain relief with minimal invasiveness. The development of this market is anticipated to be aided by a number of new technologies and therapies. Due to their efficiency and patient convenience, injectable pain treatments are anticipated to see increased use.

As the global population ages, the prevalence of chronic pain conditions is expected to increase, which will drive demand for pain therapeutic injectables. The geriatric population is particularly susceptible to chronic pain, making them a key demographic for the pain therapeutic injectables market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining Demand within the Global Market?

The market is constrained by a number of factors, including expensive injectable drug costs, adverse effects from prolonged use of opioids, and the possibility of drug abuse and addiction. Pain therapeutic injectables can be expensive, which can limit access for some patients. This is particularly true for those who do not have adequate health insurance coverage or who are underinsured.

The regulatory environment is also posing difficulties for the market, particularly when it comes to confirming the efficacy and safety of new injectable treatments before they can be released. The development and approval of new pain medications can be a lengthy and expensive process due to the strict regulatory requirements in many countries. This can limit the number of new products entering the market and slow down innovation.

Country-wise Insights

What Makes the USA a Large Market for Pain Therapeutic Injectables?

The USA dominates the global region with a total market share of around 39.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period.

The market for pain therapeutic injectables in the USA is expanding due to a number of factors. One of the contributing aspects is the increasing prevalence of chronic pain. Chronic pain is a major healthcare issue in the United States, affecting millions of people each year. This has led to a growing demand for pain management therapies, including pain therapeutic injectables.

Other than this, an increase in awareness and education regarding the advantages of injectable painkillers such as their quicker onset of action and more accurate dosing, among medical professionals and patients, is driving the market in this region. In USA, the growth of the market is also fueled by the creation of novel and sophisticated injectable medications as well as the increased availability of enhanced delivery methods. These advancements are driving growth in the market by providing better treatment options for patients.

What is the Scenario of Japan within the Pain Therapeutic Injectables Market Space?

Japan contributed around US$ 1.1 Billion revenue to the global pain therapeutic injectables market in 2022. The prevalence of chronic pain conditions is increasing in Japan, including osteoarthritis, cancer pain, and lower back pain. This has led to a growing demand for pain therapeutic injectables. Additionally, as older people are more likely to have chronic pain, Japan's aging population is fueling the demand for pain management therapies, including pain therapeutic injectables.

The development of this market has also been aided by technological developments and the accessibility of new painkillers and treatments in Japan. The demand for pain treatment injectables in Japan has also been significantly influenced by patients' and healthcare professionals' growing knowledge regarding the importance of effective pain management.

What is the Outlook of Germany in the Pain Therapeutic Injectables Market?

Germany held a market share of 25.6% in the Western Europe pain therapeutic injectables market in 2022.

The market is expanding in Germany due to the growing popularity of minimally invasive procedures for pain management, which frequently involves the use of injectable medications. Other than this, the demand for pain treatment injectables in the nation is also being fueled by the growing importance of at-home healthcare and self-administration of injectables. Overall, it is anticipated that these factors will continue to fuel the market for pain therapeutic injectables in Germany in the coming years.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Pain Therapeutic Injectables Drug Class is Driving the Market Growth?

Opioids by drug class segment held 53.4% share in the global market in 2022. Opioids are still frequently used to control pain, especially in situations where there is significant acute pain or chronic pain that does not respond to other forms of treatment. In recent years, although there has been a shift towards the use of non-opioid options for pain management, opioids still have a place in some circumstances. Overall, opioids play a substantial role in the market of therapeutic injectables for treating pain, but their usage needs to be carefully regulated and balanced with other therapies.

Which Product is a Large Concern within the Global Market?

Prescription drugs by product segment contributed around US$ 11.3 Billion in the global market in 2022. Since they are frequently used to manage pain in individuals who require more intense therapy, prescription medications play a key role in the market of therapeutic injectables for treating pain. The market for pain therapeutic injectables also has a prescription medicine sector that is significant because it offers healthcare professionals a variety of treatment alternatives to fulfill the various demands of their patients.

Which Pain Therapeutic Injectables Indication is Driving the Market Growth?

Surgical pain by indication segment held more than one-third revenue share in the global market in 2022. Injectable painkillers are in high demand because of the increasing prevalence of surgical pain conditions. As a result of tissue damage and inflammation, patients who have undergone surgery, are most likely to experience pain so, pain treatment is a crucial component of post-operative care. Since pain therapeutic injectables can offer more immediate and intense pain relief than oral drugs, these are often utilized to alleviate the discomfort due to the pain.

Which Distribution Channel Benefits the Most from the Sales within the Market?

Retail pharmacies is the leading segment with over 27.0% revenue share in 2022 globally. When it comes to distribution channel, retail pharmacies are considered a place which is quite accessible to patients in order to buy these kinds of injectable drugs. Therefore, retail pharmacies play a significant role in this market. Retail pharmacies typically stock a wide range of medications, including prescription drugs, over-the-counter medications, and other healthcare products. This makes it easy for patients to find the medications they need without having to visit multiple locations.

Competitive Landscape

Key differentiating tactics used by producers of pain therapeutic injectables include an increase in product releases and regulatory body approval, growth into other regions, and marketing approvals in other locations. The dynamics of the market have changed as a result of increasing awareness.

  • In May 2022, Teva Pharmaceuticals agreed into a settlement agreement with the Rhode Island Attorney General for the state and its subdivisions' opioid-related claims.
  • In March 2022, Pfizer Inc. stated that it had purchased Arena Pharmaceuticals to treat a variety of immune-inflammatory illnesses.

Similarly, recent developments related to companies manufacturing pain therapeutic injectables have been tracked by the team at Future Market Insights. These are available in the full report.

Report Scope as per Pain Therapeutic Injectables Industry Analysis

Attribute Details
Historical Data Available for 2018 to 2022
Forecast Period 2023 to 2033
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, Central Asia, Russia & Belarus, Balkan & Baltic Countries, and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia & New Zealand, Japan, China, South Korea, GCC Countries, Kingdom of Saudi Arabia, Türkiye, Northern Africa, South Africa, and Israel
Key Market Segments Covered Drug Class, Product, Indication, Distribution Channel and Region
Key Companies Profiled
  • AbbVie Inc. (Allergan plc)
  • Bristol Myers Squibb Co.
  • Sanofi S.A.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
  • GSK plc.
  • Abbott Laboratories, Inc.
  • Novartis AG
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Procter & Gamble
  • AstraZeneca
  • Cardinal Health
  • Perrigo Company Plc.
  • Bausch Health Companies Inc.
  • Viatris
  • Amneal Pharmaceuticals
  • Purdue Pharmaceuticals L.P.
Pricing Available upon Request

Key Market Segments Covered in the Pain Therapeutic Injectables Industry Research

Drug Class:

  • Opioids
    • Tramadol
    • Oxycodone
    • Hydrocodone
    • Other Opioids
  • NSAIDs
  • Local Anesthetics
  • Acetaminophen

Product:

  • OTC Products
  • Prescription Drugs

Indication:

  • Surgical Pain
  • Cancer Pain
  • Neuropathic Pain
  • Musculoskeletal and Joint Pain
  • Others

Distribution Channel:

  • Hospital Pharmacies
  • Specialty Clinics
  • Long Term Care Centers
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Western Europe
  • Eastern Europe
  • Central Asia
  • Russia & Belarus
  • Balkan & Baltic Countries
  • Middle East and Africa (MEA)

Frequently Asked Questions

Which countries dominate the global Pain Therapeutic Injectables market?

The United States, Japan, and China dominate the global pain therapeutic injectables market.

What is the growth forecast for the Pain Therapeutic Injectables market?

The pain therapeutic injectables market is forecast to register a CAGR of 4.5% through 2033.

How is the historical performance of the market?

The overall global painkillers market has a value of around US$ 19.3 Billion in 2022.

Which is the top trend in the Pain Therapeutic Injectables market?

Technological advancement disrupts the current market trends, such as the development of new pain medications and delivery methods.

What is the projected size of the market by 2033?

The global market size of pain therapeutic injectables is to reach US$ 30.9 Billion by 2033.

Table of Content

1. Executive Summary | Pain Therapeutic Injectables Market

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Value Added Insights

    4.1. Patient Treatment Journey

    4.2. Disease Epidemiology

    4.3. Pipeline Assessment

        4.3.1. By Drug Class

        4.3.2. Comprehensive Assessment by Phases

        4.3.3. Emerging Novel Trends

    4.4. List of Key Players, By Region

    4.5. Number of Surgeries Performed, By Region

    4.6. Key Regulations

    4.7. Reimbursement Landscape

    4.8. PESTLE Analysis

    4.9. Value chain analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure Outlook

        5.1.3. Global Painkillers Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Top Companies Historical Growth

        5.2.2. Increasing Aging Population

        5.2.3. Patent Expiration of Novel Pain Management Drugs (Opioids)

        5.2.4. Introduction of Novel Advancements in Pain Therapeutics Injectables

        5.2.5. Average Annual Spending on Pain Therapeutics Injectables

        5.2.6. Awareness of Pain Therapeutics

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

    6.1. 2022 Market Scenario

    6.2. COVID-19 and Impact Analysis

        6.2.1. By Drug Class

        6.2.2. By Product

        6.2.3. By Indication

        6.2.4. By Distribution Channel

7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033

    7.1. Historical Market Value (US$ Million) Analysis 2018 to 2022

    7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2018 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        8.3.1. Opioids

            8.3.1.1. Tramadol

            8.3.1.2. Oxycodone

            8.3.1.3. Hydrocodone

            8.3.1.4. Other Opioids

        8.3.2. NSAIDs

        8.3.3. Local Anesthetics

        8.3.4. Acetaminophen

    8.4. Market Attractiveness Analysis By Drug Class

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033

        9.3.1. Over-The-Counter (OTC) Products

        9.3.2. Prescription Drugs

    9.4. Market Attractiveness Analysis By Product

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        10.3.1. Surgical Pain

        10.3.2. Cancer Pain

        10.3.3. Neuropathic Pain

        10.3.4. Musculoskeletal & Joint Pain

        10.3.5. Others

    10.4. Market Attractiveness Analysis By Indication

11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        11.3.1. Hospital Pharmacies

        11.3.2. Specialty Clinics

        11.3.3. Long Term Care Centers

        11.3.4. Retail pharmacies

        11.3.5. Drug Stores

        11.3.6. Online Pharmacies

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region

    12.1. Introduction Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022

    12.2. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        12.2.1. North America

        12.2.2. Latin America

        12.2.3. Western Europe

        12.2.4. Eastern Europe

        12.2.5. Russia & Belarus

        12.2.6. Balkan & Baltic Countries

        12.2.7. South Asia & Pacific

        12.2.8. East Asia

        12.2.9. Central Asia

        12.2.10. Middle East & Africa

    12.3. Market Attractiveness Analysis By Region

13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. USA

            13.3.1.2. Canada

        13.3.2. By Drug Class

        13.3.3. By Product

        13.3.4. By Indication

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Product

        13.4.4. By Indication

        13.4.5. By Distribution Channel

    13.5. Market Trends

    13.6. Drivers and Restraints - Impact Analysis

    13.7. Country Level Analysis & Forecast

        13.7.1. USAMarket

            13.7.1.1. Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Drug Class

                13.7.1.2.2. By Product

                13.7.1.2.3. By Indication

                13.7.1.2.4. By Distribution Channel

        13.7.2. Canada Market

        13.7.3. Introduction

        13.7.4. Market Analysis and Forecast by Market Taxonomy

                13.7.4.1.1. By Drug Class

                13.7.4.1.2. By Product

                13.7.4.1.3. By Indication

                13.7.4.1.4. By Distribution Channel

14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. Brazil

            14.3.1.2. Mexico

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Drug Class

        14.3.3. By Product

        14.3.4. By Indication

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Product

        14.4.4. By Indication

        14.4.5. By Distribution Channel

    14.5. Market Trends

    14.6. Drivers and Restraints - Impact Analysis

    14.7. Country Level Analysis & Forecast

        14.7.1. Brazil Market

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Drug Class

                14.7.1.2.2. By Product

                14.7.1.2.3. By Indication

                14.7.1.2.4. By Distribution Channel

        14.7.2. Mexico Market

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Drug Class

                14.7.2.2.2. By Product

                14.7.2.2.3. By Indication

                14.7.2.2.4. By Distribution Channel

        14.7.3. Argentina Market

        14.7.4. Introduction

        14.7.5. Market Analysis and Forecast by Market Taxonomy

                14.7.5.1.1. By Drug Class

                14.7.5.1.2. By Product

                14.7.5.1.3. By Indication

                14.7.5.1.4. By Distribution Channel

15. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. France

            15.3.1.3. Spain

            15.3.1.4. Italy

            15.3.1.5. BENELUX

            15.3.1.6. Nordic Countries

            15.3.1.7. United Kingdom

        15.3.2. By Drug Class

        15.3.3. By Product

        15.3.4. By Indication

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Product

        15.4.4. By Indication

        15.4.5. By Distribution Channel

    15.5. Market Trends

    15.6. Drivers and Restraints - Impact Analysis

    15.7. Country Level Analysis & Forecast

        15.7.1. Germany Painkillers Market

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Drug Class

                15.7.1.2.2. By Product

                15.7.1.2.3. By Indication

                15.7.1.2.4. By Distribution Channel

        15.7.2. France Market

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Drug Class

                15.7.2.2.2. By Product

                15.7.2.2.3. By Indication

                15.7.2.2.4. By Distribution Channel

        15.7.3. Spain Market

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Drug Class

                15.7.3.2.2. By Product

                15.7.3.2.3. By Indication

                15.7.3.2.4. By Distribution Channel

        15.7.4. Italy Market

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Drug Class

                15.7.4.2.2. By Product

                15.7.4.2.3. By Indication

                15.7.4.2.4. By Distribution Channel

        15.7.5. BENELUX Market

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Drug Class

                15.7.5.2.2. By Product

                15.7.5.2.3. By Indication

                15.7.5.2.4. By Distribution Channel

        15.7.6. Nordic Countries Market

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Drug Class

                15.7.6.2.2. By Product

                15.7.6.2.3. By Indication

                15.7.6.2.4. By Distribution Channel

        15.7.7. UNITED KINGDOMMarket

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast by Market Taxonomy

                15.7.7.2.1. By Drug Class

                15.7.7.2.2. By Product

                15.7.7.2.3. By Indication

                15.7.7.2.4. By Distribution Channel

16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        16.3.1.  By Country

                16.3.1.1.1. Poland

                16.3.1.1.2. Hungary

                16.3.1.1.3. Romania

                16.3.1.1.4. Czech Republic

                16.3.1.1.5. Rest of Eastern Europe

        16.3.2. By Drug Class

        16.3.3. By Product

        16.3.4. By Indication

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Drug Class

        16.4.2. By Product

        16.4.3. By Indication

        16.4.4. By Distribution Channel

    16.5. Market Trends

    16.6. Drivers and Restraints - Impact Analysis

    16.7. Country Level Analysis & Forecast

        16.7.1. Poland Market

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Drug Class

                16.7.1.2.2. By Product

                16.7.1.2.3. By Indication

                16.7.1.2.4. By Distribution Channel

        16.7.2. Hungary Market

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Drug Class

                16.7.2.2.2. By Product

                16.7.2.2.3. By Indication

                16.7.2.2.4. By Distribution Channel

        16.7.3. Romania Market

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Drug Class

                16.7.3.2.2. By Product

                16.7.3.2.3. By Indication

                16.7.3.2.4. By Distribution Channel

        16.7.4. Czech Republic Market

            16.7.4.1. Introduction

            16.7.4.2. Market Analysis and Forecast by Market Taxonomy

                16.7.4.2.1. By Drug Class

                16.7.4.2.2. By Product

                16.7.4.2.3. By Indication

                16.7.4.2.4. By Distribution Channel

17. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        17.3.1.  By Country

            17.3.1.1. I India

            17.3.1.2. Indonesia

            17.3.1.3. Thailand

            17.3.1.4. Philippines

            17.3.1.5. Malaysia

            17.3.1.6. Vietnam

            17.3.1.7. Rest of SA

            17.3.1.8. Australia & New Zealand

        17.3.2. By Drug Class

        17.3.3. By Product

        17.3.4. By Indication

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Product

        17.4.4. By Indication

        17.4.5. By Distribution Channel

    17.5. Market Trends

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country-Level Analysis & Forecast

        17.7.1. India Market

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Drug Class

                17.7.1.2.2. By Product

                17.7.1.2.3. By Indication

                17.7.1.2.4. By Distribution Channel

        17.7.2. Indonesia Market

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Drug Class

                17.7.2.2.2. By Product

                17.7.2.2.3. By Indication

                17.7.2.2.4. By Distribution Channel

        17.7.3. Thailand Market

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast by Market Taxonomy

                17.7.3.2.1. By Drug Class

                17.7.3.2.2. By Product

                17.7.3.2.3. By Indication

                17.7.3.2.4. By Distribution Channel

        17.7.4. Philippines Market

            17.7.4.1. Introduction

            17.7.4.2. Market Analysis and Forecast by Market Taxonomy

                17.7.4.2.1. By Drug Class

                17.7.4.2.2. By Product

                17.7.4.2.3. By Indication

                17.7.4.2.4. By Distribution Channel

        17.7.5. Malaysia Market

            17.7.5.1. Introduction

            17.7.5.2. Market Analysis and Forecast by Market Taxonomy

                17.7.5.2.1. By Drug Class

                17.7.5.2.2. By Product

                17.7.5.2.3. By Indication

                17.7.5.2.4. By Distribution Channel

        17.7.6. Vietnam Market

            17.7.6.1. Introduction

            17.7.6.2. Market Analysis and Forecast by Market Taxonomy

                17.7.6.2.1. By Drug Class

                17.7.6.2.2. By Product

                17.7.6.2.3. By Indication

                17.7.6.2.4. By Distribution Channel

        17.7.7. Australia & New Zealand Market

            17.7.7.1. Introduction

            17.7.7.2. Market Analysis and Forecast by Market Taxonomy

                17.7.7.2.1. By Drug Class

                17.7.7.2.2. By Product

                17.7.7.2.3. By Indication

                17.7.7.2.4. By Distribution Channel

18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. Japan

            18.3.1.2. China

            18.3.1.3. South Korea

        18.3.2. By Drug Class

        18.3.3. By Product

        18.3.4. By Indication

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug Class

        18.4.3. By Product

        18.4.4. By Indication

        18.4.5. By Distribution Channel

    18.5. Market Trends

    18.6. Drivers and Restraints - Impact Analysis

    18.7. Country Level Analysis & Forecast

        18.7.1. Japan Market

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Drug Class

                18.7.1.2.2. By Product

                18.7.1.2.3. By Indication

                18.7.1.2.4. By Distribution Channel

        18.7.2. China Market

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Drug Class

                18.7.2.2.2. By Product

                18.7.2.2.3. By Indication

                18.7.2.2.4. By Distribution Channel

        18.7.3. South Korea Market

            18.7.3.1. Introduction

            18.7.3.2. Market Analysis and Forecast by Market Taxonomy

                18.7.3.2.1. By Drug Class

                18.7.3.2.2. By Product

                18.7.3.2.3. By Indication

                18.7.3.2.4. By Distribution Channel

19. Central Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    19.1. Introduction

    19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        19.3.1. By Drug Class

        19.3.2. By Product

        19.3.3. By Indication

        19.3.4. By Distribution Channel

    19.4. Market Attractiveness Analysis

        19.4.1. By Drug Class

        19.4.2. By Product

        19.4.3. By Indication

        19.4.4. By Distribution Channel

    19.5. Market Trends

    19.6. Drivers and Restraints - Impact Analysis  

20. Russia & Belarus Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    20.1. Introduction

    20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        20.3.1. By Drug Class

        20.3.2. By Product

        20.3.3. By Indication

        20.3.4. By Distribution Channel

    20.4. Market Attractiveness Analysis

        20.4.1. By Drug Class

        20.4.2. By Product

        20.4.3. By Indication

        20.4.4. By Distribution Channel

    20.5. Market Trends

    20.6. Drivers and Restraints - Impact Analysis

21. Balkan & Baltic Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    21.1. Introduction

    21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        21.3.1. By Drug Class

        21.3.2. By Product

        21.3.3. By Indication

        21.3.4. By Distribution Channel

    21.4. Market Attractiveness Analysis

        21.4.1. By Drug Class

        21.4.2. By Product

        21.4.3. By Indication

        21.4.4. By Distribution Channel

    21.5. Market Trends

    21.6. Drivers and Restraints - Impact Analysis

22. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033

    22.1. Introduction

    22.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022

    22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        22.3.1. By Country

            22.3.1.1. GCC Countries

            22.3.1.2. Kingdom of Saudi Arabia

            22.3.1.3. Türkiye

            22.3.1.4. Northern Africa

            22.3.1.5. South Africa

            22.3.1.6. Israel

        22.3.2. By Drug Class

        22.3.3. By Product

        22.3.4. By Indication

        22.3.5. By Distribution Channel

    22.4. Market Attractiveness Analysis

        22.4.1. By Country

        22.4.2. By Drug Class

        22.4.3. By Product

        22.4.4. By Indication

        22.4.5. By Distribution Channel

    22.5. Market Trends

    22.6. Drivers and Restraints - Impact Analysis

    22.7. Country Level Analysis & Forecast

        22.7.1. GCC Countries Market

            22.7.1.1. Introduction

            22.7.1.2. Market Analysis and Forecast by Market Taxonomy

                22.7.1.2.1. By Drug Class

                22.7.1.2.2. By Product

                22.7.1.2.3. By Indication

                22.7.1.2.4. By Distribution Channel

        22.7.2. Kingdom of Saudi Arabia Market

            22.7.2.1. Introduction

            22.7.2.2. Market Analysis and Forecast by Market Taxonomy

                22.7.2.2.1. By Drug Class

                22.7.2.2.2. By Product

                22.7.2.2.3. By Indication

                22.7.2.2.4. By Distribution Channel

        22.7.3.  Türkiye Market

            22.7.3.1. Introduction

            22.7.3.2. Market Analysis and Forecast by Market Taxonomy

                22.7.3.2.1. By Drug Class

                22.7.3.2.2. By Product

                22.7.3.2.3. By Indication

                22.7.3.2.4. By Distribution Channel

        22.7.4. Northern Africa Market

            22.7.4.1. Introduction

            22.7.4.2. Market Analysis and Forecast by Market Taxonomy

                22.7.4.2.1. By Drug Class

                22.7.4.2.2. By Product

                22.7.4.2.3. By Indication

                22.7.4.2.4. By Distribution Channel

        22.7.5. South Africa Market

            22.7.5.1. Introduction

            22.7.5.2. Market Analysis and Forecast by Market Taxonomy

                22.7.5.2.1. By Drug Class

                22.7.5.2.2. By Product

                22.7.5.2.3. By Indication

                22.7.5.2.4. By Distribution Channel

        22.7.6. Israel Market

            22.7.6.1. Introduction

            22.7.6.2. Market Analysis and Forecast by Market Taxonomy

                22.7.6.2.1. By Drug Class

                22.7.6.2.2. By Product

                22.7.6.2.3. By Indication

                22.7.6.2.4. By Distribution Channel

23. Market Structure Analysis

    23.1. Market Analysis by Tier of Companies

    23.2. Market Share Analysis of Top Players (%), 2020-2033

    23.3. Market Share Analysis, 2022

24. Competition Analysis

    24.1. Competition Dashboard

    24.2. Key Development Analysis

    24.3. Branding and Promotional Strategies

    24.4. Competition Deep Dive

        24.4.1. AbbVie Inc. (Allergan plc)

            24.4.1.1.  Overview

            24.4.1.2. Product Portfolio

            24.4.1.3. Sales Footprint

            24.4.1.4. Key Financials

            24.4.1.5. Key Developments

            24.4.1.6. SWOT Analysis

            24.4.1.7. Strategy Overview

                24.4.1.7.1. Marketing Strategy

                24.4.1.7.2. Product Strategy

                24.4.1.7.3. Channel Strategy

        24.4.2. Bristol Myers Squibb Co.

            24.4.2.1. Overview

            24.4.2.2. Product Portfolio

            24.4.2.3. Sales Footprint

            24.4.2.4. Key Financials

            24.4.2.5. Key Developments

            24.4.2.6. SWOT Analysis

            24.4.2.7. Strategy Overview

                24.4.2.7.1. Marketing Strategy

                24.4.2.7.2. Product Strategy

                24.4.2.7.3. Channel Strategy

        24.4.3. Sanofi S.A.

            24.4.3.1. Overview

            24.4.3.2. Product Portfolio

            24.4.3.3. Sales Footprint

            24.4.3.4. Key Financials

            24.4.3.5. Key Developments

            24.4.3.6. SWOT Analysis

            24.4.3.7. Strategy Overview

                24.4.3.7.1. Marketing Strategy

                24.4.3.7.2. Product Strategy

                24.4.3.7.3. Channel Strategy

        24.4.4. Boehringer Ingelheim International GmbH

            24.4.4.1. Overview

            24.4.4.2. Product Portfolio

            24.4.4.3. Sales Footprint

            24.4.4.4. Key Financials

            24.4.4.5. Key Developments

            24.4.4.6. SWOT Analysis

            24.4.4.7. Strategy Overview

                24.4.4.7.1. Marketing Strategy

                24.4.4.7.2. Product Strategy

                24.4.4.7.3. Channel Strategy

        24.4.5. Pfizer Inc.

            24.4.5.1. Overview

            24.4.5.2. Product Portfolio

            24.4.5.3. Sales Footprint

            24.4.5.4. Key Financials

            24.4.5.5. Key Developments

            24.4.5.6. SWOT Analysis

            24.4.5.7. Strategy Overview

                24.4.5.7.1. Marketing Strategy

                24.4.5.7.2. Product Strategy

                24.4.5.7.3. Channel Strategy

        24.4.6. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)

            24.4.6.1. Overview

            24.4.6.2. Product Portfolio

            24.4.6.3. Sales Footprint

            24.4.6.4. Key Financials

            24.4.6.5. Key Developments

            24.4.6.6. SWOT Analysis

            24.4.6.7. Strategy Overview

                24.4.6.7.1. Marketing Strategy

                24.4.6.7.2. Product Strategy

                24.4.6.7.3. Channel Strategy

        24.4.7. GSK plc.

            24.4.7.1. Overview

            24.4.7.2. Product Portfolio

            24.4.7.3. Sales Footprint

            24.4.7.4. Key Financials

            24.4.7.5. Key Developments

            24.4.7.6. SWOT Analysis

            24.4.7.7. Strategy Overview

                24.4.7.7.1. Marketing Strategy

                24.4.7.7.2. Product Strategy

                24.4.7.7.3. Channel Strategy

        24.4.8. Abbott Laboratories, Inc.

            24.4.8.1. Overview

            24.4.8.2. Product Portfolio

            24.4.8.3. Sales Footprint

            24.4.8.4. Key Financials

            24.4.8.5. Key Developments

            24.4.8.6. SWOT Analysis

            24.4.8.7. Strategy Overview

                24.4.8.7.1. Marketing Strategy

                24.4.8.7.2. Product Strategy

                24.4.8.7.3. Channel Strategy

        24.4.9. Novartis AG

            24.4.9.1. Overview

            24.4.9.2. Product Portfolio

            24.4.9.3. Sales Footprint

            24.4.9.4. Key Financials

            24.4.9.5. Key Developments

            24.4.9.6. SWOT Analysis

            24.4.9.7. Strategy Overview

                24.4.9.7.1. Marketing Strategy

                24.4.9.7.2. Product Strategy

                24.4.9.7.3. Channel Strategy

        24.4.10. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

            24.4.10.1. Overview

            24.4.10.2. Product Portfolio

            24.4.10.3. Sales Footprint

            24.4.10.4. Key Financials

            24.4.10.5. Key Developments

            24.4.10.6. SWOT Analysis

            24.4.10.7. Strategy Overview

                24.4.10.7.1. Marketing Strategy

                24.4.10.7.2. Product Strategy

                24.4.10.7.3. Channel Strategy

        24.4.11. Sun Pharmaceutical Industries Ltd.

            24.4.11.1. Overview

            24.4.11.2. Product Portfolio

            24.4.11.3. Sales Footprint

            24.4.11.4. Key Financials

            24.4.11.5. Key Developments

            24.4.11.6. SWOT Analysis

            24.4.11.7. Strategy Overview

                24.4.11.7.1. Marketing Strategy

                24.4.11.7.2. Product Strategy

                24.4.11.7.3. Channel Strategy

        24.4.12. Teva Pharmaceuticals Ltd.

            24.4.12.1. Overview

            24.4.12.2. Product Portfolio

            24.4.12.3. Sales Footprint

            24.4.12.4. Key Financials

            24.4.12.5. Key Developments

            24.4.12.6. SWOT Analysis

            24.4.12.7. Strategy Overview

                24.4.12.7.1. Marketing Strategy

                24.4.12.7.2. Product Strategy

                24.4.12.7.3. Channel Strategy

        24.4.13. Mallinckrodt Pharmaceuticals

            24.4.13.1. Overview

            24.4.13.2. Product Portfolio

            24.4.13.3. Sales Footprint

            24.4.13.4. Key Financials

            24.4.13.5. Key Developments

            24.4.13.6. SWOT Analysis

            24.4.13.7. Strategy Overview

                24.4.13.7.1. Marketing Strategy

                24.4.13.7.2. Product Strategy

                24.4.13.7.3. Channel Strategy

        24.4.14. Endo Pharmaceuticals Inc.

            24.4.14.1. Overview

            24.4.14.2. Product Portfolio

            24.4.14.3. Sales Footprint

            24.4.14.4. Key Financials

            24.4.14.5. Key Developments

            24.4.14.6. SWOT Analysis

            24.4.14.7. Strategy Overview

                24.4.14.7.1. Marketing Strategy

                24.4.14.7.2. Product Strategy

                24.4.14.7.3. Channel Strategy

        24.4.15. Bayer AG

            24.4.15.1. Overview

            24.4.15.2. Product Portfolio

            24.4.15.3. Sales Footprint

            24.4.15.4. Key Financials

            24.4.15.5. Key Developments

            24.4.15.6. SWOT Analysis

            24.4.15.7. Strategy Overview

                24.4.15.7.1. Marketing Strategy

                24.4.15.7.2. Product Strategy

                24.4.15.7.3. Channel Strategy

        24.4.16. F. Hoffmann-La Roche Ltd.

            24.4.16.1. Overview

            24.4.16.2. Product Portfolio

            24.4.16.3. Sales Footprint

            24.4.16.4. Key Financials

            24.4.16.5. Key Developments

            24.4.16.6. SWOT Analysis

            24.4.16.7. Strategy Overview

                24.4.16.7.1. Marketing Strategy

                24.4.16.7.2. Product Strategy

                24.4.16.7.3. Channel Strategy

        24.4.17. Procter & Gamble

            24.4.17.1. Overview

            24.4.17.2. Product Portfolio

            24.4.17.3. Sales Footprint

            24.4.17.4. Key Financials

            24.4.17.5. Key Developments

            24.4.17.6. SWOT Analysis

            24.4.17.7. Strategy Overview

                24.4.17.7.1. Marketing Strategy

                24.4.17.7.2. Product Strategy

                24.4.17.7.3. Channel Strategy

        24.4.18. AstraZeneca

            24.4.18.1. Overview

            24.4.18.2. Product Portfolio

            24.4.18.3. Sales Footprint

            24.4.18.4. Key Financials

            24.4.18.5. Key Developments

            24.4.18.6. SWOT Analysis

            24.4.18.7. Strategy Overview

                24.4.18.7.1. Marketing Strategy

                24.4.18.7.2. Product Strategy

                24.4.18.7.3. Channel Strategy

        24.4.19. Cardinal Health

            24.4.19.1. Overview

            24.4.19.2. Product Portfolio

            24.4.19.3. Sales Footprint

            24.4.19.4. Key Financials

            24.4.19.5. Key Developments

            24.4.19.6. SWOT Analysis

            24.4.19.7. Strategy Overview

                24.4.19.7.1. Marketing Strategy

                24.4.19.7.2. Product Strategy

                24.4.19.7.3. Channel Strategy

        24.4.20. Perrigo Company Plc.

            24.4.20.1. Overview

            24.4.20.2. Product Portfolio

            24.4.20.3. Sales Footprint

            24.4.20.4. Key Financials

            24.4.20.5. Key Developments

            24.4.20.6. SWOT Analysis

            24.4.20.7. Strategy Overview

                24.4.20.7.1. Marketing Strategy

                24.4.20.7.2. Product Strategy

                24.4.20.7.3. Channel Strategy

        24.4.21. Bausch Health Companies Inc.

            24.4.21.1. Overview

            24.4.21.2. Product Portfolio

            24.4.21.3. Sales Footprint

            24.4.21.4. Key Financials

            24.4.21.5. Key Developments

            24.4.21.6. SWOT Analysis

            24.4.21.7. Strategy Overview

                24.4.21.7.1. Marketing Strategy

                24.4.21.7.2. Product Strategy

                24.4.21.7.3. Channel Strategy

        24.4.22. Viatris

            24.4.22.1. Overview

            24.4.22.2. Product Portfolio

            24.4.22.3. Sales Footprint

            24.4.22.4. Key Financials

            24.4.22.5. Key Developments

            24.4.22.6. SWOT Analysis

            24.4.22.7. Strategy Overview

                24.4.22.7.1. Marketing Strategy

                24.4.22.7.2. Product Strategy

                24.4.22.7.3. Channel Strategy

        24.4.23. Amillioneal Pharmaceuticals

            24.4.23.1. Overview

            24.4.23.2. Product Portfolio

            24.4.23.3. Sales Footprint

            24.4.23.4. Key Financials

            24.4.23.5. Key Developments

            24.4.23.6. SWOT Analysis

            24.4.23.7. Strategy Overview

                24.4.23.7.1. Marketing Strategy

                24.4.23.7.2. Product Strategy

                24.4.23.7.3. Channel Strategy

        24.4.24. Purdue Pharmaceuticals L.P.

            24.4.24.1. Overview

            24.4.24.2. Product Portfolio

            24.4.24.3. Sales Footprint

            24.4.24.4. Key Financials

            24.4.24.5. Key Developments

            24.4.24.6. SWOT Analysis

            24.4.24.7. Strategy Overview

                24.4.24.7.1. Marketing Strategy

                24.4.24.7.2. Product Strategy

                24.4.24.7.3. Channel Strategy

25. Assumptions and Acronyms Used

26. Research Methodology

Recommendations

Healthcare

Chronic Pain Market

December 2022

REP-GB-16039

April 2024

312 pages

Healthcare

Injectable Drug Delivery Market

December 2021

REP-GB-393

April 2024

342 pages

Healthcare

Injectable Drug Market

June 2022

REP-GB-15073

March 2024

306 pages

Healthcare

Central Pain Syndrome Management Market

January 2023

REP-GB-16402

299 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Pain Therapeutic Injectables Market